STOCK TITAN

Mind Medicine Inc - MNMD STOCK NEWS

Welcome to our dedicated news page for Mind Medicine (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mind Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mind Medicine's position in the market.

Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). MM-120 demonstrated statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety rating scale (HAM-A) compared to placebo at Week 4. MM-120 100 µg showed a 7.6-point reduction compared to placebo at Week 4, with a clinical response rate of 78% in 100 µg and 200 µg dose groups and a 50% clinical remission rate in the 100 µg dose group at Week 4. MM-120 was generally well-tolerated with mostly mild-to-moderate adverse events. The company plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate a Phase 3 clinical program in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.46%
Tags
clinical trial
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. reported its financial results for the quarter ended September 30, 2023. Key highlights include the expected topline readout of MM-120 in GAD (Phase 2b) in Q4 2023, the anticipated topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) by the end of Q1 2024, and the Phase 1 clinical trial initiation of MM-402 in ASD in Q4 2023. The company had cash and cash equivalents of $117.7 million at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.44%
Tags
earnings
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. plans to host a conference call on November 2, 2023, to provide a corporate update and review its Q3 2023 results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
conferences earnings
Rhea-AI Summary
MindMed completes enrollment of Phase 2a study for treatment of ADHD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
clinical trial
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc announced the upcoming presentation of preclinical data of MM-402, their proprietary form of MDMA, in a model for autism spectrum disorder at the 36th Annual ECNP Congress. The study showed that MM-402 demonstrated better efficacy than S-MDMA and racemic MDMA, with enhanced pro-social effects and reduced hyperactivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
-
Rhea-AI Summary
MindMed CEO to participate in panel at TD Cowen Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
conferences
Rhea-AI Summary
MindMed completes enrollment and dosing in Phase 2b study for GAD treatment with MM-120, on track for topline results in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
clinical trial
-
Rhea-AI Summary
MindMed to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. has entered into a senior secured credit facility with K2 HealthVentures, providing financial flexibility for its clinical stage biopharmaceutical product candidates. The company's cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026. $15.0 million has been drawn at loan closing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
none
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported financial results for the quarter ended June 30, 2023. The company has cash and cash equivalents of $116.9 million. Topline readouts of MM-120 in GAD (Phase 2b) and ADHD (Phase 2a proof-of-concept) are expected in Q4 2023. MM-402 in ASD is on track for Phase 1 clinical trial initiation in Q4 2023. MindMed also entered into an exclusive license agreement with Catalent for MM-120 Zydis ODT formulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.64%
Tags
earnings
Mind Medicine Inc

Nasdaq:MNMD

MNMD Rankings

MNMD Stock Data

706.92M
33.15M
2.45%
25.44%
10.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver

About MNMD

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.